Navigation Links
NZymeCeuticals Announces the Introduction of New Bulk Ingredient 'Platinum Nattokinase' (PN20K) to Dietary Supplement Industry
Date:9/8/2008

NZymeCeuticals, Inc., (d/b/a NZyme) a company established in 2002, will begin to market "Platinum Nattokinase" (PN20K) Sept. 2008. Dr. Ralph E. Holsworth, President of NZymeCeuticals, Inc., announced Friday the company will begin to market the new line of bulk powder enzyme ingredient, nattokinase as "PN20K" to North and South America.

Durango, CO (PRWEB) September 8, 2008 -- "PN20K" is a pro-fibrinolytic enzyme that is extracted from a particular type of fermented soybean (natto) and renown in the dietary supplement industry and medical field for its "blood clot busting" abilities. "The new line has been in development for the past two years in Japan and establishes the 'platinum' standard for nattokinase." "PN20K is patent protected and manufactured by an ISO 9000 certified Japanese manufacturer," says Dr. Holsworth. A number of Japanese researchers and Dr. Holsworth collaborated on specific characteristics of nattokinase, enhancing the specificity of nattokinase's ability to breakup "cross-linked" fibrin and increasing its stability in clinical settings. In addition, PN20K significantly improves the way blood flows and enhances human microcirculation, promising novel therapeutic modalities for hypertension, coronary artery disease, diabetes, cerebrovascular accidents and deep vein thrombosis.

Dr. Holsworth first introduced nattokinase to the United States in 2002. Since then, the ingredient has gained much attention largely due to its naturally occurring "blood clot busting" ability. During this time, Dr. Holsworth and Dr. Sumi (the discoverer of nattokinase) have met several times in Japan and the USA to discuss the therapeutic properties of the enzyme and its future medical use. Over the years, Drs. Holsworth and Sumi continue to collaborate on the studies and findings of nattokinase. Initial research indicates PN20K has the potential to significantly impact cardiovascular diseases because of its ability to change chemical and physical characteristics of blood, providing a "one-two punch." "We simply don't see these positive effects with typical pharmaceutical drugs," says Dr. Holsworth.

In Japan, the enzyme has an annual 15 billion yen market. Since its introduction to the U.S. market, bulk sales for the enzyme have experienced increased growth and demand. With different manufacturers of nattokinase from all over the world, the activity, stability and purity of the product varies significantly. NZymeCeuticals' bulk ingredients undergo third-party testing for quality assurance and quality control as well as to preserving the integrity of the new ingredient. Clinical research using PN20K as the therapeutic agent is well underway.

http://www.nzymeceuticals.com

###

Read the full story at http://www.prweb.com/releases/nattokinase/holsworth/prweb1294934.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services
2. Z Trim Holdings, Inc. Announces Private Placement Funding
3. The Risk Management and Patient Safety Institute Announces Agreement With Pioneering Health Care Simulation Organization, PSO One
4. Cogdell Spencer Announces First Synergy Project in Pensacola, Florida
5. Conde Nast Media Group Announces Performance of Just Stand Up to be Fed Live from the Stage at FASHION ROCKS to ABC, CBS and NBCs Simultaneous Broadcast of Stand Up To Cancer Nationwide Fund-Raising Event On September 5th
6. LIFE Foundation Announces 2008 realLIFEstories Award Recipients to Illustrate Benefits of Life and Disability Insurance
7. Elbit Imaging Ltd. Announces Second Quarter Results for 2008
8. Custom Briefings Announces Launch of Endocrine Daily Briefing
9. Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss
10. Versus Technology Announces Third Quarter Results
11. Replidyne Announces Restructuring of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading ... Word(TM) Online(TM), which enables sleep physicians to create and edit their interpretation reports. ... and provides a familiar interface that does not require additional training to use. ...
(Date:4/28/2017)... Grants Pass, OR (PRWEB) , ... April 28, ... ... Adetutu Ijose, http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to ... to bookmark and read organized content on topics such as home care (generally) as ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology: